CYC-116
CYC-116 inhibits aurora kinases B and C (AurB, AurC), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer chemotherapeutic activity and is currently in clinical trials. CYC-116 inhibits proliferation of a variety of cancer cells.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18854209
| Cas No. |
693228-63-6 |
|---|---|
| Purity |
≥98% |
| Formula |
C18H20N6OS |
| Formula Wt. |
368.46 |
| IUPAC Name |
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine |
| Appearance |
Yellow Powder |
Kamei H, Jackson RC, Zheleva D, et al. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor. J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):407-34. PMID: 20694801.
Wang S, Midgley CA, Scaërou F, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78. PMID: 20462263.
